AIP
REGN icon

Avail Investment Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Avail Investment Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$293K Buy
470
+209
+80% +$142K 0.23% 124
2026
Q1 		$202K Buy
+261
New +$200K 0.22% 126

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Avail Investment Partners's REGN Position: Q2 2026 in Review

Avail Investment Partners increased its Regeneron Pharmaceuticals (REGN) stake by 80% in Q2 2026, buying an estimated $142K and bringing the position to 470 shares worth $293K. The position accounts for 0.23% of the portfolio, ranked #124.

Avail Investment Partners first reported a position in REGN in Q1 2026 and has held it in 2 quarters since. 1,327 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Avail Investment Partners held 470 shares of Regeneron Pharmaceuticals worth $293K as of Q2 2026.
  • Avail Investment Partners bought 209 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $142K.
  • Regeneron Pharmaceuticals made up 0.23% of Avail Investment Partners's portfolio in Q2 2026, its #124 holding.
  • Avail Investment Partners first reported a position in Regeneron Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 1,327 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Avail Investment Partners's 13F filing for Q2 2026, filed 31 Jul 2026.